...
首页> 外文期刊>Neoplasma: Journal of Experimental and Clinical Oncology >BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.
【24h】

BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.

机译:BCNU-DBD(二溴调节醇)化疗治疗复发性幕上性间变性星形细胞瘤和胶质母细胞瘤。

获取原文
获取原文并翻译 | 示例

摘要

Our aim was to investigate the effect of BCNU and DBD combined chemotherapy in patients with recurrent malignant gliomas. Forty-six patients were treated with combined chemotherapy. Out of 26 patients with anaplastic astrocytomas 11 were originally low-grade where no postoperative radiotherapy was applied. Fifteen patients with anaplastic astrocytoma responded well to the chemotherapy and 9 survived longer than one year. Median survival time was 14 months. Complete response of recurrent glioblastoma did not occur and only 4 patients survived longer than one year. Median survival time was 7 months. Ratio of patients with response and stable disease was 70 and 55 %, respectively. BCNU and DBD combination proved to be an effective combination for recurrent malignant gliomas. It was remarkable that patients' survival with primary or secondary lower grade astrocytoma were significantly longer than that in patients with glioblastomas. Treatment of lower grade tumors, even at their malignant recurrences is promising.
机译:我们的目的是研究BCNU和DBD联合化疗对复发性恶性神经胶质瘤患者的疗效。 46例患者接受了联合化疗。在26例间变性星形细胞瘤患者中,有11例原属于低度,未进行术后放疗。 15例间变性星形细胞瘤患者对化疗反应良好,9例存活时间超过一年。中位生存时间为14个月。没有发生复发性胶质母细胞瘤的完全反应,只有4例患者存活超过一年。中位生存时间为7个月。有反应和稳定疾病的患者比例分别为70%和55%。 BCNU和DBD组合被证明是复发性恶性神经胶质瘤的有效组合。值得注意的是,原发性或继发性低度星形细胞瘤患者的生存期明显长于胶质母细胞瘤患者。即使是恶性复发,低级肿瘤的治疗也是有希望的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号